Related Experiment Videos

Antimicrobial therapy of experimental group B streptococcal infection in mice

Insights

Combining ampicillin with gentamicin significantly improves survival and bacterial clearance in Group B beta-hemolytic streptococci (GB-BHS) infections in mice compared to ampicillin alone. This suggests a potential superior treatment strategy for neonatal GB-BHS infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Group B beta-hemolytic streptococci (GB-BHS) are a major cause of severe neonatal infections.
  • Previous in vitro studies indicated enhanced bacterial killing with ampicillin plus gentamicin versus ampicillin monotherapy.

Purpose of the Study:

  • To evaluate the in vivo efficacy of ampicillin plus gentamicin compared to ampicillin alone for treating experimental GB-BHS infections.
  • To determine the impact of combination therapy on survival rates and bacterial clearance in a murine model.

Main Methods:

  • Mice were experimentally infected with GB-BHS.
  • Treatment groups included ampicillin alone, ampicillin plus gentamicin, and untreated controls.
  • Survival rates and bacteremia levels were monitored.

Main Results:

  • Untreated mice exhibited high mortality within 10-48 hours.
  • Ampicillin-gentamicin combination therapy demonstrated improved survival rates compared to ampicillin alone, regardless of treatment timing (established infection or single dose).
  • The combination therapy significantly accelerated the clearance of bacteremia.

Conclusions:

  • Combination therapy with ampicillin or penicillin G plus gentamicin may offer superior outcomes for GB-BHS infections compared to beta-lactam monotherapy.
  • Clinical reconsideration of current treatment guidelines for GB-BHS infections is warranted.
  • This combination therapy holds promise for treating neonatal and other patient populations susceptible to GB-BHS.

Related Concept Videos